STAT6 specific shRNA inhibits proliferation and induces apoptosis in colon cancer HT-29 cells

Cancer Letters

Volumn 243, Issue 1, 2006, Pages 38-46

  Zhang, Mingsheng ^a   Zhou, Yunfeng ^a   Xie, Conghua ^a   Zhou, Fuxiang ^a   Chen, Yun ^b   Han, Guang ^a   Zhang, Wen Jie ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Apoptosis; Colon cancer; RNA interference; shRNA; STAT6

Indexed keywords

SHORT HAIRPIN RNA; STAT6 PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; FLOW CYTOMETRY; HT29 CELLS; HUMANS; PLASMIDS; RNA INTERFERENCE; RNA, DOUBLE-STRANDED; STAT6 TRANSCRIPTION FACTOR; TRANSFECTION;

EID: 33749234543     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.11.020     Document Type: Article

References (33)

1. Gudkov A.V., Zelnick C.R., Kazarov A.R., Thimmapaya R., Suttle D.P., Beck W.T., et al. Isolation ofgenetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc. Natl Acad. Sci. USA 90 (1993) 3231-3235
2. Collins F.S., Green E.D., Guttmacher A.E., and Guyer M.S. A vision for the future of genomic research. Nature 422 (2003) 835-847
3. Novina C.D., and Sharp P.A. The RNAi revolution. Nature 430 (2004) 161-164
4. Matzke M., Matzke A., and Kooter M.J. RNA: guiding gene silencing. Science 293 (2001) 1980-1983
5. Tuschl T. Expanding small RNA interference. Nat. Biotechnol. 20 (2002) 446-448
6. Agami R. RNAi and related mechanisms and their potential use for therapy. Curr. Opin. Chem. Biol. 6 (2002) 829-834
7. Darnell Jr. J.E., Kerr I.M., and Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264 (1994) 1415-1421
8. Ihle J.N., and Kerr I.M. Jaks and stats in signaling by the cytokine receptor superfamily. Trends. Genet. 11 (1995) 3951-3963
9. Schindler C., and Darnell Jr. J.E. Transcriptional responses to polypeptide ligands: the Jak-STAT pathway. Annu. Rev. Biochem. 64 (1995) 621-651
10. Takeda K., Tanaka T., Shi W., Matsumoto M., Minami M., Kashiwamura S., et al. Essential role of Stat6 in IL-4 signaling. Nature 380 (1996) 627-630
11. Takeda K., Kamanaka M., Tanaka T., Kishimoto T., and Akira S. Impaired IL-13-mediated functions of macrophages in Stat6-deficient mice. J. Immunol. 157 (1996) 3220-3222
12. Kaplan M.H., Schindler U., Smiley S.T., and Grusby M.J. Stat6 is required for mediating responses to IL-4 and for the development if Th2 cells. Immunity 4 (1996) 1-20
13. Shimoda K., Deursen J., Sangster M.Y., Sarawar S.R., Carson R.T., Tripp R.A., et al. Lack of IL-4-induced Th2 responses and IgE class switching in mice with disrupted Stat6 gene. Nature 380 (1996) 630-633
14. Shirakawa I., Deichmann K.A., Izuhara I., Mao I., Adra C.N., and Hopkin J.M. Atopy and asthma: genetic variants of IL-4 and IL-13 signaling. Immunol. Today 21 (2000) 60
15. Gooch J.L., Christy B., and Yee D. STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells. Neoplasia 4 (2002) 324-331
16. Skinnider B.F., Elia A.J., and Gascoyne R.D. Signal transduer and activator of transcription 6 is frequently activated in hodgkin and reed-sternberg cells of hodgkin lymphoma. Blood 99 (2002) 618-626
17. Zhang W.J., Koltun W.A., Thompson J.L., Anna F.T., and Chorney M.J. Genetic control of interleukin-4-induced activation of the human signal transducer and activator of transcription 6 signaling pathway. Hum. Immunol. 64 (2003) 402-416
18. Zhang W.J., Koltun W.A., Thompson J.L., Anna F.T., Galka E., Poritz L.S., et al. Human B lymphoblast cell lines defective of Stat6 signaling produce high levels of prooinflammatory cytokines IL-12, TNF-αand IFN-γ. Int. J. Oncol. 24 (2004) 447-453
19. Zhang W.J., Zhou Y.F., and Xie C.H. Defective IL-4/Stat6 signaling correlates with increased apoptosis of human EBV-lymphoblastoid cells and mouse spleen cells. J. Biomed. Eng. 22 (2005) 103-104
20. Vellonen K.S., Honkakoski P., and Urtti A. Substrates and inhibitors of efflux proteins interfere with the MTT assay in cells and may lead to underestimation of drug toxicity. Eur. J. Pharm. Sci. 23 (2004) 181-188
21. Nelms K., Keegan A.D., Zamorano J., Ryan J.J., and Paul W.E. The IL-4 receptor: signaling mechanisms and biologic functions. Annu. Rev. Immunol. 17 (1999) 701
22. Tomkinson A., Duez C., Lahn M., and Gelfand E.W. Adoptive transfer of T cells induces airway hyperresponsiveness independently of airway eosinophilia but in a signal transducer and activator of transcription 6-dependent manner. J. Allergy Clin. Immunol. 109 (2002) 810-816
23. Ni Z., Lou W., and Lee S.O. Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma. J. Urol. 167 (2002) 1859-1862
24. Suzanne O., Michael J.G., and Virginia K.C. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J. Immunol. 165 (2000) 6015-6019
25. null phenotype human lymphocytes exhibit increased apoptosis. J. Surg. Res. 122 (2004) 14-20
26. Fire A., Xu S., and Montgomery M.K. Potent and specific genetic interference by double stranded RNA in Caenorhabditis elegans. Nature 391 (1998) 806-811
27. Dorsett Y., and Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat. Rev. Drug Discov. 3 (2004) 318-329
28. Kim J.H., Park H.H., and Lee C.E. IGF-1 potentiation of IL-4-induced CD23/Fc(epsilon)RII expression in human B cells. Mol. Cells 15 (2003) 307-312
29. Kaplan M.H., Daniel C., and Schindler U. Stat proteins control lymphocyte proliferation by regulating P27Kip1 expression. Mol. Cell. Biol. 18 (1998) 1996-2003
30. Levings M.K., and Schrader J.W. IL-4 inhibits the production of TNF-alpha and IL-12 by STAT6-dependent and -independent mechanisms. J. Immunol. 162 (1999) 5224
31. Rothstein T.L. Inducible resistance to Fab-mediated apoptosis in B cells. Cell Res. 10 (2000) 245
32. Ostrand-Rosenberg S., Grusby M.J., and Clements V.K. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J. Immunol. 165 (2000) 6015
33. Kacha A.K., Fallarino F., Markiewicz M.A., and Gajewski T.F. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J. Immunol. 165 (2000) 6024